3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
4
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Carcinoma
1
Interventions
pembrolizumab
3
temsirolimus
1
spartalizumab
1
poly ICLC
1
patritumab
1
durvalumab
1
atezolizumab
1
advexin
1
Tetanus Toxoid
1
Sunitinib
1
Rifampin
1
Radiation
1
Nivolumab
1
Midazolam
1
Ketoconazole
1
Ipilimumab
1
Interleukin-15
1
Brentuximab Vedotin
1
Blood Specimen Collection
1
Axitinib
1
3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione
1
2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid
1
1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Axitinib
×
Lymphoid
×
Clear all
NCT00700258
2024-09-23
STAR-TOR
Pfizer
Completed
1,520 enrolled
24 charts